Drugs / LID/ΔM2-2/1030s
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04520659 | Mar 2022 → Apr 2024 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LID/ΔM2-2/1030s | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04520659 ↗ |
| Known as | RSV LID/ΔM2-2/1030s | “RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0)” NCT04520659 ↗ |
| Modality | Vaccine | “recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine” NCT04520659 ↗ |
| Route | Other | “administered as nose drops” NCT04520659 ↗ |